Literature DB >> 31804856

Review of Current Policy Strategies to Reduce US Cancer Drug Costs.

Angela K Green1, Jennifer A Ohn1, Peter B Bach1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31804856      PMCID： PMC6994254          DOI： 10.1200/JCO.19.01628

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Medicaid cost containment and access to prescription drugs.

Authors:  Peter J Cunningham
Journal:  Health Aff (Millwood)       Date:  2005 May-Jun       Impact factor: 6.301

Review 2.  Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Authors:  Andrea Navarria; Valentina Drago; Lucia Gozzo; Laura Longo; Silvana Mansueto; Giacomo Pignataro; Filippo Drago
Journal:  Value Health       Date:  2014-11-11       Impact factor: 5.725

3.  Expansion of the Medicare 340B Payment Program: Hospital Participation, Prescribing Patterns and Reimbursement, and Legal Challenges.

Authors:  Peter B Bach; Rachel E Sachs
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

4.  Cancer drugs in the United States: Justum Pretium--the just price.

Authors:  Hagop M Kantarjian; Tito Fojo; Michael Mathisen; Leonard A Zwelling
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

5.  Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer.

Authors:  Christopher S Lathan; Angel Cronin; Reginald Tucker-Seeley; S Yousuf Zafar; John Z Ayanian; Deborah Schrag
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

6.  Overspending driven by oversized single dose vials of cancer drugs.

Authors:  Peter B Bach; Rena M Conti; Raymond J Muller; Geoffrey C Schnorr; Leonard B Saltz
Journal:  BMJ       Date:  2016-02-29

7.  The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.

Authors:  Rena M Conti; Peter B Bach
Journal:  Health Aff (Millwood)       Date:  2014-10       Impact factor: 6.301

8.  Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

Authors:  Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

9.  Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".

Authors:  Jalpa A Doshi; Pengxiang Li; Amy R Pettit; J Samantha Dougherty; Ashley Flint; Vrushabh P Ladage
Journal:  Am J Manag Care       Date:  2017-03       Impact factor: 2.229

10.  Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review.

Authors:  Aaron P Mitchell; Jason S Rotter; Esita Patel; Daniel Richardson; Stephanie B Wheeler; Ethan Basch; Daniel A Goldstein
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777
View more
  6 in total

Review 1.  Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question.

Authors:  M Sureda; E Calvo; J J Mata; V Escudero-Ortiz; E Martinez-Navarro; A Catalán; J Rebollo
Journal:  Clin Transl Oncol       Date:  2021-02-13       Impact factor: 3.405

2.  Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital.

Authors:  Koichi Matsuo; Hisanaga Nomura; Masanobu Uchiyama; Motoyasu Miyazaki; Osamu Imakyure
Journal:  BMC Health Serv Res       Date:  2020-11-09       Impact factor: 2.655

3.  Weighing Costs and Benefits in the Economics of Cancer Care.

Authors:  Scott D Ramsey; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

4.  Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.

Authors:  Ross F Harrison; Shuangshuang Fu; Charlotte C Sun; Hui Zhao; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Am J Obstet Gynecol       Date:  2021-02-04       Impact factor: 10.693

5.  The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis.

Authors:  Michal Sarfaty; Assaf Moore; Ashley M Regazzi; Aaron P Mitchell; Jonathan E Rosenberg
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639

Review 6.  Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: A systematic review.

Authors:  Raymond Henderson; Peter Keeling; Declan French; Dave Smart; Richard Sullivan; Mark Lawler
Journal:  Mol Oncol       Date:  2021-07-19       Impact factor: 6.603
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.